Leveraging inpatient antimicrobial stewardship infrastructure to improve antimicrobial-prescribing at hospital discharge
利用住院患者抗菌药物管理基础设施改善出院时的抗菌药物处方
基本信息
- 批准号:10421218
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdmission activityAdverse drug eventAntimicrobial ResistanceAttitudeCase MixesCenters for Disease Control and Prevention (U.S.)CharacteristicsClinicalClostridium difficileCommunicable DiseasesCommunitiesDataDevelopmentDoseFeedbackFosteringFundingFutureGoalsHealth PrioritiesHealthcareHomeHospital AdministrationHospitalsInfectionInfrastructureInpatientsInterventionInterviewKnowledgeLength of StayLiteratureManualsMeasurementMethodologyModelingMonitorOutcomePaperPatient AdmissionPatientsPerceptionPerformancePharmaceutical PreparationsProcessPromoting Action on Research Implementation in Health Services frameworkPublic HealthQualitative MethodsResourcesRiskRisk FactorsSafetyServicesSiteSite VisitStandardizationStructureSurveysTargeted ResearchTimeVariantVeteransVeterans Health AdministrationVisitWorkacute careantimicrobialbasedashboarddesignemerging antimicrobial resistanceevidence baseimprovedinnovationpatient orientedpatient safetypatient subsetspilot testprogramstool
项目摘要
Background: Antimicrobial overuse is one of the strongest risk factors for the emergence of antimicrobial
resistance, an urgent public health problem. Antimicrobial stewardship programs (ASPs) are hospital-based
programs that can reduce unnecessary inpatient antimicrobial use and are therefore an essential tool for
addressing the crisis of antimicrobial resistance. ASPs are mandated in VHA.
Significance: VHA hospitals are only required to monitor their inpatient antimicrobial use. However, at least
40% of antimicrobial exposure associated with a VHA hospital stay is prescribed at hospital discharge and is
taken by the patient after discharge (i.e. post-discharge). These post-discharge antimicrobial prescriptions are
frequently unnecessary or sub-optimal. Reducing post-discharge antimicrobial overuse will minimize patient
harm, such as Clostridioides difficile infections, antimicrobial resistance, and adverse drug events.
Innovation and Impact: This proposal will address two critical gaps in the literature. First, standard ASP
metrics do not capture post-discharge antimicrobial use and therefore miss a substantial amount of hospital-
related antimicrobial exposure. This proposal will evaluate factors that contribute to variation in post-discharge
antimicrobial use across patients and hospitals in order to inform both metric development and the design of
future stewardship interventions. Second, while there are evidence-based strategies for safely reducing
inpatient antimicrobial use, it is unclear how current inpatient ASP activities can decrease post-discharge
antimicrobial overuse. This proposal will explore how inpatient ASP infrastructure, which all VHA hospitals are
expected to have, can be leveraged to reduce unnecessary post-discharge antimicrobial-prescribing.
Specific Aims: Aim 1: Identify factors that contribute to variation in post-discharge antimicrobial use in VHA
acute-care admissions across all facilities by evaluating potential patient-level, hospital-level, and
environmental effects. Identify hospitals that have low observed-to-expected post-discharge antimicrobial use,
low risk-adjusted inpatient antimicrobial use, and perform well on clinical outcomes in antimicrobial-treated
patients. Aim 2: Determine whether being admitted to a hospital with a discharge-focused stewardship process
is associated with less post-discharge antimicrobial exposure, after adjusting for differences in case-mix, ID
expertise, inpatient antimicrobial exposure, and the intensity of inpatient ASP activities. Aim 3: Using qualitative
methods, evaluate attitudes and processes that impede or foster reductions in unnecessary post-discharge
antimicrobial use. We will perform site visits at 6 high- and 4 low-performing sites, as identified in Aim 1.
Methodology: Aim 1 will use VINCI data and linear mixed models to identify factors that influence post-
discharge antimicrobial use. Aim 1 will also rank hospitals on their performance on inpatient and post-
discharge antimicrobial use plus associated clinical outcomes. In Aim 2, we will leverage VINCI data and
findings from a mandatory hospital-level stewardship survey conducted in VHA during November 2020. We will
evaluate the effect of a discharge-specific stewardship process on post-discharge antimicrobial use. In Aim 3,
we will conduct semi-structured interviews with key stakeholders at 10 hospitals to explore determinants of
post-discharge antimicrobial overuse and perceptions of the post-discharge antimicrobial use metric that we
developed in Aim 1. Our approach will be based in the i-PARIHS framework.
Next Steps/Implementation: The standardized hospital-level metrics we develop in Aim 1 could be
incorporated into an interactive ASP dashboard our Patient Safety Center of Inquiry has already built and is
pilot-testing in VISN 23. Our findings from Aims 2 and 3 could be incorporated into future stewardship surveys
within VHA while informing the processes local ASPs choose to implement to reduce post-discharge
antimicrobial overuse. Our findings could serve as the basis for a multicenter, audit-and-feedback trial focused
on stewardship at hospital discharge and future work around re-designing ASP processes at discharge.
背景:抗菌药物的过度使用是导致抗菌药物出现的最大危险因素之一。
耐药性是一个紧迫的公共卫生问题。抗菌药物管理计划(ASP)以医院为基础
可以减少不必要的住院抗菌药物使用的计划,因此是一个重要的工具,
解决抗菌药物耐药性危机。ASP在VHA中被授权。
意义:VHA医院只需要监测其住院抗菌药物的使用情况。但至少
与VHA住院相关的40%的抗菌剂暴露在出院时处方,
患者出院后(即出院后)服用。这些出院后的抗菌处方是
通常是不必要的或次优的。减少出院后抗菌药物的过度使用将最大限度地减少患者
危害,如艰难梭菌感染、抗菌素耐药性和药物不良事件。
创新和影响:本提案将解决文献中的两个关键空白。一、标准ASP
指标没有捕获出院后抗菌药物的使用,因此错过了大量的医院-
相关的抗菌剂暴露。该提案将评估导致出院后变化的因素
抗菌药物在患者和医院中的使用,以便为指标的制定和
未来的管理干预。其次,虽然有基于证据的安全减少
住院患者抗菌药物使用情况,目前尚不清楚目前住院患者ASP活动如何减少出院后
抗生素滥用该提案将探讨如何住院ASP基础设施,其中所有VHA医院是
预期具有的,可以用来减少不必要的出院后抗菌药物处方。
具体目的:目的1:确定导致VHA出院后抗菌药物使用变化的因素
通过评估潜在的患者水平、医院水平和
环境影响。确定出院后抗菌药物使用低于预期的医院,
低风险调整的住院患者抗菌药物使用,并在抗菌药物治疗的临床结局中表现良好
患者目标2:确定是否入住一家以出院为重点的管理流程的医院
在调整病例组合、ID、
专业知识、住院患者抗菌药物暴露和住院患者ASP活动强度。目标3:使用定性
方法,评估阻碍或促进减少不必要的出院后的态度和过程
抗菌剂的使用。我们将在目标1中确定的6个高性能研究中心和4个低性能研究中心进行研究中心访视。
方法:目标1将使用芬奇数据和线性混合模型来确定影响后
排出抗菌药物。Aim 1还将根据医院在住院和术后的表现对医院进行排名。
出院抗菌药物使用情况及相关临床结局。在目标2中,我们将利用芬奇数据,
2020年11月在VHA进行的强制性医院管理调查结果。我们将
评价出院特定管理过程对出院后抗菌药物使用的影响。在目标3中,
我们将对10家医院的主要利益相关者进行半结构化访谈,以探讨
出院后抗菌药物过度使用和对出院后抗菌药物使用指标的看法,
在Aim 1中开发。我们的方法将基于i-PARIHS框架。
下一步/实施:我们在目标1中开发的标准化医院级指标可以是
整合到我们的患者安全调查中心已经建立的交互式ASP仪表板中,
在VISN 23中进行试点测试。我们在目标2和3中的发现可以纳入未来的管理调查
在VHA内部,同时告知当地ASP选择实施的流程,以减少出院后
抗生素滥用我们的研究结果可以作为一个多中心的基础,
关于出院时的管理工作和未来围绕出院时重新设计ASP流程的工作。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Daniel Livorsi其他文献
Daniel Livorsi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Daniel Livorsi', 18)}}的其他基金
Leveraging inpatient antimicrobial stewardship infrastructure to improve antimicrobial-prescribing at hospital discharge
利用住院患者抗菌药物管理基础设施改善出院时的抗菌药物处方
- 批准号:
10620189 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Improving antimicrobial use at hospitals that lack infectious disease specialists
改善缺乏传染病专家的医院抗菌药物的使用
- 批准号:
9696670 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Improving antimicrobial use at hospitals that lack infectious disease specialists
改善缺乏传染病专家的医院抗菌药物的使用
- 批准号:
10216345 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Improving antimicrobial use at hospitals that lack infectious disease specialists
改善缺乏传染病专家的医院抗菌药物的使用
- 批准号:
10175014 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Improving antimicrobial use at hospitals that lack infectious disease specialists
改善缺乏传染病专家的医院抗菌药物的使用
- 批准号:
10295036 - 财政年份:2017
- 资助金额:
-- - 项目类别: